加载中
NASDAQHealthcareBiotechnology
最新数据
US$1.76
−US$0.14 · -7.37%
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
常规交易时段
US$1.76
−US$0.14 · -7.37%
盘中时间采用ET。市场数据可能有所延迟。
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
日内区间
当前US$1.76
52周区间
当前US$1.76
盘中时间采用ET。市场数据可能有所延迟。
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
日内区间
当前US$1.76
52周区间
当前US$1.76
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 135.6万 USD | 100.6万 USD | 53.6万 USD | — | — |
| 毛利 | −135.6万 USD | −100.6万 USD | −53.6万 USD | — | — |
| 研究与开发 | 5999万 USD | 6399.2万 USD | 4548.8万 USD | 2394.9万 USD | 1371.8万 USD |
| 销售、一般及管理费用 | 2412.4万 USD | 2520.7万 USD | 2121.3万 USD | 870.8万 USD | 246.6万 USD |
| 营业费用 | 8275.8万 USD | 8819.3万 USD | 6670.1万 USD | 3265.7万 USD | 1618.4万 USD |
| 利息收入 | 647.9万 USD | 920.1万 USD | 703.7万 USD | — | — |
| 折旧和摊销 | 135.6万 USD | 100.6万 USD | 53.6万 USD | 36.4万 USD | 3.7万 USD |
| 营业利润 | −8411.4万 USD | −8919.9万 USD | −6723.7万 USD | −3265.7万 USD | −1618.4万 USD |
| 净利润 | −7790.5万 USD | −8055.6万 USD | −6038.8万 USD | −3116.7万 USD | −1624.3万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$21.83
上涨空间 1140.34%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI114.02万0.00%2.3万亿 USD0.03%US$381.09-0.13%
Vanguard Extended Market ETFVXF81.42万0.00%954亿 USD0.05%US$232.69-0.36%
iShares Micro-Cap ETFIWC11.79万0.01%13.17亿 USD0.60%US$180.05-0.89%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM11万0.09%1.16亿 USD0.73%US$15.68-1.06%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.35万0.00%61.96亿 USD0.26%US$68.485+0.24%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMU.S. Vector Equity Portfolio ETF Class SharesDXUVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
